FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Private Equity Owners Weigh WildFire Energy Exit at $4 Billion Valuation

By

-- WildFire Energy's backers are considering a sale that could exceed $4 billion, Reuters said Friday, citing people familiar with the matter.

Warburg Pincus and Kayne Anderson have begun exploring a potential exit from the US shale operator, with sources indicating a valuation above $4 billion, including debt.

Jefferies will oversee the sale process, with bankers expected to begin formally marketing the company to buyers in the coming weeks, the report added, citing four people familiar with the matter.

Elevated crude prices, which have pushed past $100 per barrel amid Middle East tensions, are increasing asset values and encouraging producers to pursue sale opportunities.

Operating in the Eagle Ford basin, WildFire produces roughly 50,000 net barrels of oil equivalent per day, making it one of the larger privately held players in South Texas.

Sources said uncertain market conditions could still affect negotiations, adding that no agreement is certain and valuations may shift from the current $4 billion estimate, according to the report.

Since Warburg and Kayne Anderson invested in 2019, the company has expanded through acquisitions, including assets purchased from APA Corp and Chesapeake Energy.

has reached out to Wildfire, Warburg, Kayne Anderson, and Jefferies for any comments.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.

$GEHC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.

$LII